In contrast to the single report of activating ALK mutations (ALK-L1198F and ALK-G1201E) in the full length receptor [12], a number of articles have reported ALK fusion genes in thyroid cancer, where they appear to represent a small fraction of papillary thyroid carcinoma (PTC). This evidence concerns the gene ALK and differentiated thyroid carcinoma.